Piper Sandler Starts Inventiva SA (IVA) at Overweight

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Inventiva SA (NASDAQ: IVA) with a Overweight rating and a price target of $26.00.

The analyst comments: "We are initiating coverage on Inventiva with an OW rating and $26 PT as the company is developing its lead asset, lanifibranor (oral pan-PPAR agonist), in MASH with Ph3 NATiV3 topline in 2H26. Recognize, IVA is trading at a market cap of ~$650M, representing a 14x valuation gap vs MDGL ($9.2B) in MASH, which we believe provides a lucrative buying opportunity given IVA has an oral asset de-risked for PoS. Thus, considering REZDIFFRA's successful launch progress so far in MASH, this highlights the high unmet needs, where lanifibranor has especially attractive positioning for T2D MASH patients given its unique benefits to glycemic control/insulin resistance (~10.6M F2-3 US MASH patients estimated by 2030, with ~15-20% T2D co-morbidity rate). Ultimately, we believe Ph3 NATiV3 in 2H26 is de-risked and could be a key stock-moving event to further highlight lanifibranor's compelling MASH value proposition and drive share gains."

For an analyst ratings summary and ratings history on Inventiva SA click here. For more ratings news on Inventiva SA click here.

Shares of Inventiva SA closed at $4.59 yesterday.

You May Also Be Interested In